Iterion Presents Cancer Drug Data

Iterion Therapeutics will present new data on its first-in-class TBL1 inhibitor, tegavivint, at the AACR Annual Meeting. Tegavivint targets Wnt-driven cancers, representing a novel approach in oncology research. The presentation of this data at a major scientific conference underscores the company's progress in developing innovative treatments for challenging diseases and highlights potential advancements in cancer therapy.